Evidence map›Paper›PMID 37636316›Full record

ArticleNAR cancer2023

Co-evolution of

Andrej Zivanovic, Jeffrey T Miller, Sarah A Munro, Todd P Knutson, Yingming Li, Courtney N Passow, Pijus Simonaitis, Molly Lynch, LeAnn Oseth, Shuang G Zhao and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Extrachromosomal DNA and cancer: function, formation, and clinical implications.Journal of experimental & clinical cancer research : CR · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Andrej ZivanovicMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Jeffrey T MillerMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.
Sarah A MunroMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.
Todd P KnutsonMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.
Yingming LiMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Courtney N PassowUniversity of Minnesota Genomics Center, University of Minnesota, Minneapolis, MN, USA.
Pijus SimonaitisDepartment of Computer Science, Princeton University, Princeton, NJ, USA.
Molly LynchMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
LeAnn OsethMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Shuang G ZhaoDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.
Felix Y FengDepartments of Radiation Oncology, Urology, and Medicine, University of California San Francisco, San Francisco, CA, USA.
Pernilla WikströmDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, USA.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, WA, USA.
Christine HenzlerMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.
Benjamin J RaphaelDepartment of Computer Science, Princeton University, Princeton, NJ, USA.
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-7827-5579

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0M
AR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9M
Comprehensive and Robust Tools for Analysis of Tumor Heterogeneity and EvolutionU24CA248453 · NCI · PRINCETON UNIVERSITY · PI Benjamin Raphael · 2020 to 2026
$4.7M
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCR01CA256157 · NCI · DUKE UNIVERSITY · PI ARMSTRONG, ANDREW J, DEHM, SCOTT M. · 2020 to 2025
$3.2M
NCI NIH HHS P01 CA163227NCI NIH HHS P30 CA077598NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA174777NCI NIH HHS R01 CA256157NCI NIH HHS U24 CA248453
6 · The paper itself

Abstract

Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via mechanisms that include

Identifiers

PMID37636316
PMCPMC10448862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.